Ernexa Therapeutics to Present at Oxford Global’s Cell 2025

Core Insights - Ernexa Therapeutics is set to present at Cell 2025, focusing on innovations in cell therapies for advanced cancer and autoimmune diseases [1][3] - The presentations will emphasize the importance of smart trial design and early regulatory engagement to accelerate clinical progress in cell therapy development [1][2] Company Overview - Ernexa Therapeutics (NASDAQ: ERNA) specializes in developing innovative cell therapies, particularly through engineering induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs) [4] - The company’s lead product, ERNA-101, aims to activate the immune system to target cancer cells, with a specific focus on ovarian cancer treatment [5] Event Details - The Cell 2025 event will take place on November 11-12, 2025, in London, UK, and is a key gathering for professionals in bioprocessing and advanced therapies [3] - Sanjeev Luther, President and CEO of Ernexa, will participate in a panel discussion addressing funding, innovation, and regulatory strategies for advancing their iMSC platform [2]